MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326898 | Name: BMS-181100 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMS-181100, also known as BMY-14802; BMY-14802-1, is a sigma receptor antagonist and a 5-HT1A agonist with antipsychotic effects and potential useful for the treatment of schizophrenia. BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats. BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors. BMY-14802 reverses amphetamine-induced changes in neostriatal single-unit activity in freely moving rats. BMY 14802 increases expression of proneurotensin mRNA in the rat striatum.

Chemical Structure

BMS-181100 HCl
BMS-181100 HCl
CAS#105565-55-7 (HCl)

Theoretical Analysis

MedKoo Cat#: 326898

Name: BMS-181100 HCl

CAS#: 105565-55-7 (HCl)

Chemical Formula: C18H23ClF2N4O

Exact Mass: 0.0000

Molecular Weight: 384.86

Elemental Analysis: C, 56.18; H, 6.02; Cl, 9.21; F, 9.87; N, 14.56; O, 4.16

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BMS-181100; BMS181100; BMS181100; BMY-14802; BMY 14802; BMY14802; BMY-14802-1; BMS-181100 HCl; BMS-181100 hydrochloride.
IUPAC/Chemical Name
1-(4-fluorophenyl)-4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)butan-1-ol hydrochloride
InChi Key
NIBVEFRJDFVQLM-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H22F2N4O.ClH/c19-15-5-3-14(4-6-15)17(25)2-1-7-23-8-10-24(11-9-23)18-21-12-16(20)13-22-18;/h3-6,12-13,17,25H,1-2,7-11H2;1H
SMILES Code
OC(C1=CC=C(F)C=C1)CCCN2CCN(C3=NC=C(F)C=N3)CC2.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 105565-56-8(BMY-14802-1 Free) 105565-55-7(BMY-14802-1)

Preparing Stock Solutions

The following data is based on the product molecular weight 384.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bhide N, Lindenbach D, Surrena MA, Goldenberg AA, Bishop C, Berger SP, Paquette MA. The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat. Psychopharmacology (Berl). 2013 Jun;227(3):533-44. doi: 10.1007/s00213-013-3001-4. Epub 2013 Feb 7. PubMed PMID: 23389756; PubMed Central PMCID: PMC3657017. 2: Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology (Berl). 2009 Jul;204(4):743-54. doi: 10.1007/s00213-009-1505-8. Epub 2009 Mar 13. Erratum in: Psychopharmacology (Berl). 2009 May;204(1):185-7. PubMed PMID: 19283364; PubMed Central PMCID: PMC2845289. 3: Vanecek SA, Essman WD, Taylor DP, Woods JH. Discriminative stimulus characteristics of BMY 14802 in the pigeon. J Pharmacol Exp Ther. 1998 Jan;284(1):1-9. PubMed PMID: 9435153. 4: Matos FF, Korpinen C, Yocca FD. 5-HT1A receptor agonist effects of BMY-14802 on serotonin release in dorsal raphe and hippocampus. Eur J Pharmacol. 1996 Dec 12;317(1):49-54. PubMed PMID: 8982718. 5: Okumura K, Ujike H, Akiyama K, Kuroda S. BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats. J Neural Transm (Vienna). 1996;103(10):1153-61. PubMed PMID: 9013402. 6: Weiner I, Traub A, Rawlins JN, Smith AD, Feldon J. The sigma ligand BMY-14802 as a potential antipsychotic: evidence from the latent inhibition model in rats. Behav Pharmacol. 1995 Jan;6(1):46-54. PubMed PMID: 11224311. 7: Terleckyj I, Sonsalla PK. The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors. J Pharmacol Exp Ther. 1994 Apr;269(1):44-50. PubMed PMID: 7513362. 8: Gewirtz GR, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, Borison R. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology. 1994 Feb;10(1):37-40. PubMed PMID: 7910021. 9: Zhang J, Chiodo LA, Freeman AS. Further characterization of the effects of BMY 14802 on dopamine neuronal activity. Synapse. 1993 Dec;15(4):276-84. PubMed PMID: 7908761. 10: Shiue CY, Bai LQ, Shiue GG, Rysavy JA, Pleus RC, Hui H, Frick MP, Catt JD. Synthesis of (+/-)-[18F]BMY 14802, its enantiomers and their anatomical distributions in rodents. Nucl Med Biol. 1993 Jul;20(5):625-30. PubMed PMID: 8358348. 11: Ding YS, Fowler JS, Dewey SL, Wolf AP, Logan J, Gatley SJ, Volkow ND, Shea C, Taylor DP. Synthesis and PET studies of fluorine-18-BMY 14802: a potential antipsychotic drug. J Nucl Med. 1993 Feb;34(2):246-54. PubMed PMID: 8094094. 12: Taylor DP, Eison MS, Moon SL, Schlemmer RF Jr, Shukla UA, VanderMaelen CP, Yocca FD, Gallant DJ, Behling SH, Boissard CG, et al. A role for sigma binding in the antipsychotic profile of BMY 14802? NIDA Res Monogr. 1993;133:125-57. Review. PubMed PMID: 8232511. 13: Wang Z, Haracz JL, Rebec GV. BMY-14802, a sigma ligand and potential antipsychotic drug, reverses amphetamine-induced changes in neostriatal single-unit activity in freely moving rats. Synapse. 1992 Dec;12(4):312-21. PubMed PMID: 1361249. 14: Levant B, Nemeroff CB. Further studies on the modulation of regional brain neurotensin concentrations by antipsychotic drugs: focus on haloperidol and BMY 14802. J Pharmacol Exp Ther. 1992 Jul;262(1):348-55. PubMed PMID: 1625208. 15: Levant B, Merchant KM, Dorsa DM, Nemeroff CB. BMY 14802, a potential antipsychotic drug, increases expression of proneurotensin mRNA in the rat striatum. Brain Res Mol Brain Res. 1992 Feb;12(4):279-84. PubMed PMID: 1349718. 16: Contreras PC, Gray NM, Ragan DM, Lanthorn TH. BMY-14802 protects against ischemia-induced neuronal damage in the gerbil. Life Sci. 1992;51(14):1145-9. PubMed PMID: 1518377. 17: Kanzaki A, Okumura K, Ujike H, Tsuchida K, Akiyama K, Otsuki S. BMY-14802 reverses the reduction of striatal dopamine release induced by (+)-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine. J Neural Transm Gen Sect. 1992;90(2):137-44. PubMed PMID: 1361127. 18: White IM, Ciancone MT, Haracz JL, Rebec GV. A lever-release version of the conditioned avoidance response paradigm: effects of haloperidol, clozapine, sulpiride, and BMY-14802. Pharmacol Biochem Behav. 1992 Jan;41(1):29-35. PubMed PMID: 1347175. 19: Ujike H, Kanzaki A, Okumura K, Akiyama K, Otsuki S. Sigma (sigma) antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sci. 1992;50(16):PL129-34. PubMed PMID: 1313134. 20: Bristow LJ, Baucutt L, Thorn L, Hutson PH, Noble A, Beer M, Middlemiss DN, Tricklebank MD. Behavioural and biochemical evidence of the interaction of the putative antipsychotic agent, BMY 14802 with the 5-HT1A receptor. Eur J Pharmacol. 1991 Oct 29;204(1):21-8. PubMed PMID: 1839533.